Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Matthew Anderson

Matthew Anderson MD PhD

  • Sylvia K. Reitman Chair in Discovery and Innovation at Harrington Discovery Institute at University Hospitals in Cleveland, Ohio
  • Senior Attending Physician and Professor of Pathology in the Division of Neuropathology at Case Western Reserve University
  • Visiting Professor in the Department of Paediatrics, University of Oxford

Dr Matthew Anderson, MD, PhD joined the Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford and Harrington Discovery Institute at University Hospitals dedicated to advancing rare disease breakthroughs, as Co-Director in early 2025. He holds the Sylvia K. Reitman Chair in Discovery and Innovation at Harrington Discovery Institute at University Hospitals in Cleveland, Ohio, and he is a Senior Attending Physician, and Professor of Pathology in the Division of Neuropathology at Case Western Reserve University. Dr Anderson is also a Visiting Professor at the University of Oxford.

Dr Anderson brings an extraordinary depth of expertise to the OHC mission, with a background that bridges medicine, neuroscience, and biotechnology. He holds a BS in Chemistry from Cornell College, followed by an MD and PhD from the University of Iowa, where he studied medicine, physiology, and biophysics. His training in pathology and neuropathology took him from the University of Iowa Hospitals to Harvard Medical School, where he later became Chief of Neuropathology.

He joined OHC from a position as VP and Head, Neuroscience Therapeutic Focus Area at Regeneron Pharmaceuticals, leading a team of 45 scientists. He has also conducted pioneering research in neuroscience and immunology as a research fellow at MIT.